Dextran Hydrogel Encapsulation for Immune-Isolated Cell Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing hydrogels for cell therapy are unable to provide long-lasting encapsulation of cells while maintaining biocompatibility, immune isolation, and mechanical stability, and often suffer from cell sedimentation during crosslinking and poor handling properties.
Innovation Solution
A cross-linked dextran polymer with anionic groups and specific central linker radicals, such as polyethylene glycol or poly(oxazoline), combined with hyaluronic acid or its salts, to create a hydrogel with tunable properties for controlled drug release and cell encapsulation, ensuring biocompatibility and mechanical stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If existing hydrogels are used for cell encapsulation, then cell therapy is possible, but long-lasting encapsulation and immune isolation cannot be achieved simultaneously
Solution Approach 1:
The patent employs a composite hydrogel system combining dextran polymer chains with specific crosslinkers containing polyethylene glycol or poly(oxazoline) segments. This composite structure creates a dual-function material: the dextran backbone provides structural integrity for long-term encapsulation, while the PEG/POx crosslinkers create a hydrophilic, biocompatible interface that reduces immune recognition and foreign body response, enabling both prolonged duration and immune isolation.
Solution Approach 2:
The patent systematically varies key parameters including the molecular weight of dextran (5-1000 kDa), the degree of substitution (0.001-0.4), and the crosslinker architecture (2-8 arms). By optimizing these parameters, the hydrogel achieves a balanced network structure that provides mechanical stability for long-term encapsulation while maintaining sufficient mesh size and hydrophilicity to prevent immune cell infiltration and reduce immunogenicity.
2Strength
If hydrogel crosslinking is performed to improve mechanical stability, then structural integrity is enhanced, but cell sedimentation occurs during crosslinking
Solution Approach 1:
The patent incorporates cells into the hydrogel precursor solution before crosslinking occurs. The crosslinking reaction is then initiated in situ, allowing the gel network to form around the cells uniformly. This preliminary incorporation prevents cell sedimentation because the crosslinking process locks cells in place as the gel sets, rather than attempting to maintain uniform distribution during a separate crosslinking step where gravity would cause sedimentation.
Solution Approach 2:
The patent uses hyaluronic acid or its salts as an intermediary component in the hydrogel formulation. This biocompatible polymer acts as a spacer and stabilizer during crosslinking, preventing direct cell-cell contact that would lead to aggregation and sedimentation. The hyaluronic acid maintains cell suspension uniformity while the crosslinking proceeds, and also contributes to the overall mechanical stability of the final hydrogel structure.
3Object-affected harmful factors
If hydrogel thickness is reduced to improve biocompatibility and cell proximity to tissue, then immune response decreases, but mechanical strength and handling properties deteriorate
Solution Approach 1:
The patent creates a composite network where dextran chains provide structural framework and the PEG/POx crosslinkers provide mechanical reinforcement through their flexible, elastic nature. This composite architecture allows thin hydrogel implants to maintain sufficient mechanical strength for handling during minimally invasive surgery while the thin profile ensures close cell-tissue proximity and reduced foreign body response. The multifunctional crosslinkers act as molecular springs that dissipate stress, preventing fracture in thin geometries.
Solution Approach 2:
The patent employs multifunctional crosslinkers with 2-8 arms that create a non-uniform crosslinking density distribution. Regions with higher crosslinker armality provide localized mechanical reinforcement, while other regions maintain higher mesh size for nutrient diffusion and cell viability. This local quality variation allows thin hydrogels to have sufficient overall mechanical strength for handling while maintaining biocompatibility and close tissue integration throughout the implant volume.
4Reliability
If dextran substitution degree is increased to improve cell encapsulation properties, then cell survival improves, but hydrogel stability and mechanical properties worsen
Solution Approach 1:
The patent optimizes the dextran substitution degree within the specific range of 0.001-0.4, finding the optimal balance point where sufficient hydroxyl groups remain available for crosslinking while enough are substituted to provide the desired cell-friendly properties. This controlled parameter change ensures that the hydrogel maintains adequate crosslinking density for mechanical stability and structural integrity, while the substituted groups provide hydrophilicity and biocompatibility that enhance cell survival without compromising overall hydrogel stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The hydrogel provides long-lasting cell encapsulation, immune isolation, and improved cell survival with reduced sedimentation, enabling controlled drug release and mechanical stability suitable for minimally invasive surgery.
Implementation Method 1
They have the ability to absorb and retain large amounts of water. This is known as the swelling of hydrogels.
Implementation Method 2
a good permselectivity, defined as the selective permeability toward biological elements according to their size or molecular weight
Implementation Method 3
a low degradability, in particular a low biodegradability, or no biodegradability, or a good in vivo stability, in order for the incorporated cells not to escape in the organism of the patient and the host cells not to penetrate in the implant
Data Source
AI summary
A hydrogel includes the crosslinked dextran polymer of the invention and/or a hydrogel that further includes biological cells. The hydrogel has a therapeutic use for treating a disorder or disease in a mammal wherein the disorder or disease is due to lack or malfunction of endocrine function of pancreas organ. An implant includes the hydrogel and further includes a ring and a net.